Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome.
$1.63-4.12%
报价 2026-11-06
市值
$90.3M
EV
$95M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -30.0%
$1.62$2.33
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SEERSeer, Inc. | $90.3M | -4.1% | -4.1% | 47% | – | – | – | |
| KYMRKymera Therapeutics, Inc. | $11.25B | +2.8% | +48.6% | 100% | – | – | – | |
| PHVSPharvaris N.V. | $2.4B | +5.7% | – | 0% | – | – | – | |
| NRIXNurix Therapeutics, Inc. | $1.67B | +3.1% | -34.9% | -139.4% | – | – | – | |
| MLYSMineralys Therapeutics, Inc. | $1.36B | +0.6% | – | 0% | – | – | – | |
| ORICORIC Pharmaceuticals, Inc. | $914.2M | +3.9% | – | 0% | – | – | – | |
| GLUEMonte Rosa Therapeutics, Inc. | $901.8M | +3.1% | -67.4% | 95.3% | – | – | – | |
| SANASana Biotechnology, Inc. | $709.5M | +1.3% | – | 0% | – | – | – | |
| CGEMCullinan Therapeutics, Inc. | $695.1M | +4.7% | +142.3% | 0% | – | – | – | |
| 同行中位数 | – | – | +6.9% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。